| ★ | How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD | | 109 | Estados Unidos | |
| 3 | Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials | | 681 | Estados Unidos | 76 |
| 17 | Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment | | 374 | Estados Unidos | 69 |
| 5 | Afrezza’s Pediatric Approval and Improving Adolescent Diabetes Care | | 160 | Estados Unidos | 72 |
| 1 | Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD | | 152 | Estados Unidos | 77 |
| 12 | FIND-CKD Expands Finerenone Evidence Beyond Diabetic CKD, With Rajiv Agarwal, MD | | 131 | Estados Unidos | 70 |
| 7 | Total Plaque Volume Indicates Patients With 0 CAC May Still be at Risk | | 120 | Estados Unidos | 71 |
| 2 | Ruxolitinib, Tapinarof, Roflumilast: What's New for Pediatric AD | | 102 | Estados Unidos | 76 |
| 16 | VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes | | 96 | Estados Unidos | 70 |
| 11 | MAESTRO-NASH: Resmetirom May Reduce Cardiovascular Risk in MASH, With or Without Statins | | 86 | Estados Unidos | 70 |
| 19 | Juana Hutchinson-Colas, MD, OB/GYN | RWJBarnabas Health @rwjbarnabashealth | 86 | Estados Unidos | 69 |
| 6 | Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients | ATS 2026 | | 68 | Estados Unidos | 71 |
| 10 | Omalizumab vs Oral Immunotherapy for Multifood Allergy | | 65 | Estados Unidos | 70 |
| 8 | Closing Gaps in IgA Nephropathy Diagnosis and Treatment, With Brad Rovin, MD | | 60 | Estados Unidos | 71 |
| 4 | Implications of the Phase 4 Trial of Metreleptin in Patients With General Lipodystrophy | | 55 | Estados Unidos | 72 |
| 20 | Metreleptin-Neutralizing Antibodies Do Not Impact Treatment Outcomes in Generalized Lipodystrophy | | 40 | Estados Unidos | 69 |
| 15 | FMD Peak Systolic Velocity May Lead to Comprehensive Clinical Guidelines | | 33 | Estados Unidos | 70 |
| 9 | HPA-Axis Assessment Allows for Improved Corticosteroid Response Analysis | | 32 | Estados Unidos | 71 |
| 13 | Diagnosing Non-IgE Food Hypersensitivity | Brian Lacy, MD, PhD | EAC 2026 | | 31 | Estados Unidos | 70 |
| 14 | Key Non-Medication Clinical Pearls for Dermatologists, With Matthew Zirwas, MD | | 21 | Estados Unidos | 70 |
| 18 | How Should Clinicians Address the Link Between Atopic Dermatitis and Allergy? With Jay Lieberman, MD | | 13 | Estados Unidos | 69 |